3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
|
|
|
- CAS-Nr.
- 1092578-46-5
- Englisch Name:
- 3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
- Synonyma:
- (3R,4S)-Tofacitinib;Tofacitinib-14;Tofacitib impurity A;Tofatinib Impurity A;Tofacitinib IMpurity E;RS-tofacitinib citirate;Tofacitinib Impurity A(3R,4S);Azilsartan medoxomil impurity340;Tofacitinib Impurity A (3R,4S)-Tofacitinib;(3R,4S)-Tofacitinib (Tofacitinib Impurity)
- CBNumber:
- CB62642729
- Summenformel:
- C16H20N6O
- Molgewicht:
- 312.3696
- MOL-Datei:
- 1092578-46-5.mol
|
3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile Eigenschaften
- Schmelzpunkt:
- >108°C (dec.)
- Dichte
- 1.296
- storage temp.
- Refrigerator
- L?slichkeit
- Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly, Heated)
- Aggregatzustand
- Solid
- pka
- 6.04±0.60(Predicted)
- Farbe
- Pale Yellow to Yellow
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
(3R,4S)-Tofacitinib is an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor (CP-690,550) that has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases.
3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 98)Lieferanten
1092578-46-5()Verwandte Suche:
- 3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
- 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4S)-
- RS-tofacitinib citirate
- Tofacitinib IMpurity E
- Tofacitinib Impurity A(3R,4S)
- (3R,4S)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile
- (3R,4S)-4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-beta-oxo-1-piperidinepropanenitrile
- Tofacitinib impurity 10/(3R,4S)-Tofacitinib/3-((3R,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile
- Tofacitinib Impurity A (3R,4S)-Tofacitinib
- Tofacitinib-14
- Tofacitib impurity A
- Azilsartan medoxomil impurity340
- 3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitr
- (3R,4S)-Tofacitinib
- Tofatinib Impurity A
- 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3R,4S)-
- (3R,4S)-Tofacitinib (Tofacitinib Impurity)
- (3R,4S)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile
- 1092578-46-5
